Journal of Mahatma Gandhi Institute of Medical Sciences, 2013 Insulin analogues have revolutionized the treatment of diabetes mellitus, and the advent of newer insulin analogues have provided better glycemic control with lesser incidence of hypoglycemia.
Vishakha V Jain, Omprakash Gupta
doaj +3 more sources
A comparison of health‐related quality of life (health utility) between insulin degludec and insulin glargine: a meta‐analysis of phase 3 trials [PDF]
, 2013 Aim: To evaluate health-related quality of life (health utility) scores in patients with diabetes receiving insulin degludec (IDeg) or insulin glargine (IGlar).
Nick Freemantle +4 more
openalex +4 more sources
IDeglira vs insulin degludec for type 2 diabetes: a systematic review and meta-analysis [PDF]
Frontiers in EndocrinologyObjectivesThis systematic review and meta-analysis was to evaluate and compare the efficacy and safety profiles of IDegLira versus insulin degludec in the management of type 2 diabetes (T2D).MethodsA comprehensive search was systematically conducted ...
Yang Liu +6 more
doaj +2 more sources
Glargine and degludec: Solution behaviour of higher dose synthetic insulins [PDF]
Scientific Reports, 2017 Single, double and triple doses of the synthetic insulins glargine and degludec currently used in patient therapy are characterised using macromolecular hydrodynamic techniques (dynamic light scattering and analytical ultracentrifugation) in an attempt ...
Gary G. Adams +10 more
doaj +3 more sources
Insulin Degludec/Liraglutide [PDF]
Hospital Pharmacy, 2017 Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing
Danial E. Baker
openaire +3 more sources
Degludec insulin: A novel basal insulin
Indian Journal of Endocrinology and Metabolism, 2011 This paper reviews a novel insulin analogue, degludec, which has the potential to emerge as an ideal basal insulin. It reviews the limitations of existing basal insulin and analogues, and highlights the need for a newer molecule.
Sanjay Kalra +3 more
doaj +3 more sources
Continuous Glucose Monitoring and Hypoglycaemia Metrics With Once‐Weekly Basal Insulin Fc Versus Insulin Degludec: A Systematic Review and Meta‐Analysis [PDF]
Endocrinology, Diabetes & MetabolismIntroduction Once‐weekly basal insulin Fc (BIF) offers a promising alternative to daily basal insulin by reducing injection burden while maintaining glycaemic control.
Saaed Abunada +13 more
doaj +2 more sources
Use of insulin degludec in pregnancy: two case reports and a literature review
Endocrine and Metabolic Science, 2020 As of now, insulin Degludec has no indication for use in pregnancy, because of the lack of studies that prove its safety for foetus. However it isn't infrequent that some women conceive while treating with insulin Degludec.
E. Sprio +5 more
doaj +2 more sources
Switching from Insulin Degludec plus Dipeptidyl Peptidase-4 Inhibitor to Insulin Degludec/Liraglutide Improves Glycemic Variability in Patients with Type 2 Diabetes: A Preliminary Prospective Observation Study [PDF]
Journal of Diabetes Research, 2022 Incretins reduce glycemic variability (GV) in patients with type 2 diabetes, but it is unknown whether switching from a combination of basal insulin and a DPP-4 inhibitor to insulin degludec/liraglutide (IDegLira) improves GV. We performed an exploratory
Yuki Oe +11 more
doaj +2 more sources
Effects of dulaglutide combined with insulin degludec on glucose fluctuations and appetite in type 2 diabetes [PDF]
Frontiers in Endocrinology, 2023 IntroductionThe aim of this study was to describe appetite and glucose fluctuation in type 2 diabetes mellitus patients initiating treatment with dulaglutide combined with insulin degludec.MethodsThis retrospective study of patients identified adults ...
Jinxin Huang +7 more
doaj +2 more sources